Phase III study of latanoprost ophthalmic solution 0.005% in patients with open angle glaucoma
Latest Information Update: 12 Mar 2023
At a glance
- Drugs Latanoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Laboratoire Thea
Most Recent Events
- 12 Mar 2023 New trial record
- 03 Mar 2023 Results published in the Thea media release.
- 03 Mar 2023 According to Thea media release, company announced the presentation of phase III data on IYUZEH by Jason Bacharach, MD at the 2023 American Glaucoma Society (AGS) Annual Meeting.